This finding was subsequently confirmed in independent studies which demonstrated the potent anti-metastatic effects of inhibiting BCL3 by shRNA in human breast cancer xenografts [14] and a direct correlation between BCL3 expression and metastatic potential in vivo [112]. This evidence concerns the gene BCL3 and breast carcinoma.